// App-Quantinova.ai

9085 : Improved survival following implementation of next-generation sequencing in routine diagnostics of advanced lung cancer: results of the German Network Genomic Medicine.

Researchers

Presenter

  • Anna Kostenko

Principal Investigators

  • Sebastian Yves Friedrich Michels

  • Jana Fassunke

  • Matthias Scheffler

  • Sabine Merkelbach-Bruse

  • Rieke Nila Fischer

  • Merle Gerigk

  • Juliane Sueptitz

  • Florian Kron

  • Jan Peter Glossmann

  • Reinhard Buettner

  • Juergen Wolf

Medical Centers

  • Department 1 for Internal Medicine, Center for Integrated Oncology Koln-Bonn, University Hospital Cologne, Cologne, Germany

  • Lung Cancer Group Cologne, Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital Cologne, Cologne, Germany

  • Institute for Pathology, University Hospital of Cologne, Center for Integrated Oncology, Cologne, Germany

  • Lung Cancer Group Cologne, Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital Cologne, Cologne, Germany

  • Institute for Pathology, University Hospital of Cologne, Center for Integrated Oncology, Cologne, Germany

  • Institute of Pathology, University Hospital of Cologne, Cologne, Germany

  • Institute of Pathology, University Hospital of Cologne, Cologne, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Lung Cancer

Biomarkers

  • Anaplastic lymphoma Kinase

  • Proto-oncogene tyrosine-protein kinase ROS

  • Epidermal growth factor receptor

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Methadone hydrochloride

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved